title: Liver-kidney transplantation to cure atypical HUS: still an option post-eculizumab?
abstract: Patients with end-stage renal disease (ESRD) due to atypical HUS (aHUS) now have several potential options that can enable successful kidney transplantation. This editorial addresses these options by considering key factors that are important when making an individual treatment decision.
authors.affiliation: Mount Sinai Medical School, 1 Gustave L. Levy Pl, New York, NY, 10029, USA, jeff.saland@mssm.edu.
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Saland
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D065766:Atypical Hemolytic Uremic Syndrome; D017242:Complement Factor H / Q000172:deficiency* / Q000235:genetics; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000601:surgery*; D000081208:Hereditary Complement Deficiency Diseases; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000150:complications*; D016030:Kidney Transplantation; D016031:Liver Transplantation; D009154:Mutation; D010951:Plasma Exchange; D015432:Glomerulonephritis, Membranoproliferative
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C493495:CFH protein, human; D007166:Immunosuppressive Agents; D017242:Complement Factor H; C481642:eculizumab